NCT02214771View on ClinicalTrials.gov

Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients

CompletedOBSERVATIONAL
Enrollment

296

Participants

Timeline

Start Date

September 3, 2014

Primary Completion Date

March 27, 2017

Study Completion Date

August 17, 2017

Conditions
Clostridium Difficile Infection
Interventions
DRUG

Fidaxomicin

oral

DRUG

Treatment for CDI other than fidaxomicin Type

Oral

Trial Locations (24)

Unknown

Site, Béthune

Site, Bordeaux

Site, Boulogne-Billancourt

Site, Caen

Site, Chambéry

Site, Clermond-Ferrand

Site, Clichy

Site, Dijon

Site, Garches

Site, La Tronche

Site, Lille

Site, Lyon

Site, Marseille

Site, Morlaix

Site, Mulhouse

Site, Nantes

Site, Nîmes

Site, Orléans

Site, Paris

Site, Poitiers

Site, Reims

Site, Rennes

Site, Roubaix

Site, Soissons

All Listed Sponsors
lead

Astellas Pharma S.A.S.

INDUSTRY

NCT02214771 - Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients | Biotech Hunter | Biotech Hunter